Videos

Transplant-Ineligible Multiple Myeloma: The SWOG0777 Study

Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

Defining High-Risk Multiple Myeloma

Nisha Joseph, MD, presents the case of a 78-year-old man with transplant-ineligible multiple myeloma and discusses treatment strategy.

Sagar Lonial, MD;Nisha Joseph, MD;Jonathan L. Kaufman, MD;Ajay K. Nooka, MD

GALAXY: DFS by Stage and ACT Receipt in ctDNA-Positive Patients

Experts discuss how they define frail and high-risk patients with multiple myeloma and their treatment approaches for these patient populations.

Stacey A. Cohen, MD;Mark Lewis, MD

Choosing Therapies for Patients with Advanced Renal Cell Carcinoma

Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.

Tom Powles, MBBS, MRCP, MD;Brian Shimkus, MD

GALAXY: DFS by ctDNA Status at Weeks 4 and 12 Post Surgery

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

Stacey A. Cohen, MD;Mark Lewis, MD

Perspectives on COVID-19 Prophylaxis and Vaccination

GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.

John F. D. Dipersio, MD, PhD;Pashna N. Munshi, MD;Yi-Bin Chen, MD;Hannah Choe, MD

Cytoreductive Nephrectomies for Renal Cell Carcinoma

To close the discussion, panelists reflect on their practices’ guidance on long-acting antibody prophylaxis and vaccination against COVID-19 for patients with graft-versus-host-disease (GVHD).

Scott S. Tykodi, MD, PhD;Thomas E. Hutson, DO, PharmD

Alina Markova, MD, on Topical Ruxolitinib Mechanism of Action in Cutaneous Chronic GVHD

Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.

Alina Markova, MD

Exciting Developments in the HER2+ Breast Cancer Treatment Landscape

Alina Markova, MD, speaks to the mechanism of action of topical ruxolitinib INCB018424 phosphate 1.5% cream vs oral ruxolitinib and other topical therapies used in the treatment of non-sclerotic and superficially sclerotic chronic cutaneous graft-versus-host disease.

Sarah M. Tolaney, MD, MPH

The Role of Maintenance Therapy in HER2+ Breast Cancer

Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.

Sarah M. Tolaney, MD, MPH

Discussing Treatment Decisions with Patients with Early-Stage HER2+ Breast Cancer

Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.

Sarah M. Tolaney, MD, MPH

Considerations for Patient-Focused, Shared Decision-Making in RCC

A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.

David Aggen, MD, PhD;Arnab Basu, MD, MPH, FACP;Robert S. Alter, MD;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Patient-Specific Factors Impacting Treatment Choices in RCC

Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.

David Aggen, MD, PhD;Robert S. Alter, MD;Arnab Basu, MD, MPH, FACP;Mehmet Asim Bilen, MD;Chung-Han Lee, MD, PhD, Memorial Sloan Kettering Cancer Center

Uday R. Popat, MD, Reviews Post-Transplant Cyclophosphamide Vs Tacrolimus and Methotrexate to Prevent GVHD in AML/MDS

Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.

Uday R. Popat, MD

Case Presentation 1: Selecting Therapy in Transplant-Ineligible NDMM

Uday R. Popat, MD, spoke about how well post-transplant cyclophosphamide vs tacrolimus plus methotrexate to prevent graft-vs-host disease was performed in this trial.

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 17th 2022

Centering discussion on a patient case of transplant-ineligible newly diagnosed multiple myeloma, experts consider how they would approach workup and management.

NDMM Management: Assessing Response and Determining Duration of Therapy

Shaji Kumar, MD, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic;David Dingli, MD, PhD;Prashant Kapoor, MD

May 17th 2022

Comprehensive insight on optimizing newly diagnosed multiple myeloma management, ranging from response assessment to use of consolidation and maintenance therapy.

ELEVATE-RR Study Overview

Michael R. Bishop, MD;Bruce B. Bank, MD

Introduction and CLL Background

Dr Bishop reviews the ELEVATE-RR trial enrollment strategy.

Michael R. Bishop, MD;Bruce B. Bank, MD

Clinical Case Presentation: A 66-Year-Old Woman with ER+ HER2+ Invasive Ductal Carcinoma and Brain Metastases

Michael R. Bishop, MD, introduces the 2021 Journal of Clinical Oncology publication, “Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial” and invites Bruce B. Bank, MD, to comment on the typical patients with chronic lymphocytic leukemia (CLL) he sees in his clinical practice.

Sara Hurvitz, MD;Ruta Rao, MD;Stefania Maraka, MD

Novel Agents Under Evaluation for HER2+ Breast Cancer and Brain Metastases

Sara Hurvitz, MD, presents the case of a 66-year-old woman with ER+ HER2+ invasive ductal carcinoma and brain metastases.

Sara Hurvitz, MD;Stefania Maraka, MD;Ruta Rao, MD

David M. O’Malley, MD, Talks Next Steps for Treatment in Endometrial Cancer

A look at exciting clinical trials enrolling patients with HER2+ breast cancer and leptomeningeal disease, a previously unheard-of opportunity.

David O'Malley, MD, The Ohio State University Comprehensive Cancer Center

IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC

David M. O’Malley, MD, spoke about where the future of treatment is heading for patients with endometrial cancer.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

CheckMate-816: Neoadjuvant Chemoimmunotherapy for NSCLC

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

Charu Aggarwal, MD, MPH;Benjamin P. Levy, MD;Harvey I. Pass, MD;Heather Wakelee, MD

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD

HyperCVAD in Frontline ALL

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Xiaoli Mi, MD;Varun Narendra, MD

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD

Treatment Options After Progression on Frontline Maintenance Therapy

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

Petros Grivas, MD, PhD;Shilpa Gupta, MD;Peter H. O’Donnell, MD, PhD;Thomas Powles, MBBS, MD, MRCP;Guru Sonpavde, MD